Thermo Fisher Scientific (TMO) has been a dominant player, exploiting its
growth opportunities in the biopharma applications and omics research field with its next-generation mass spectrometers. Amidst market undercurrents, the company's stock is considered as a buy opportunity due to its oversold situation coupled with its position as one of the best medical device stocks. Despite recent share falls,
TMO has continued to invest in enhancing its innovation profile while initiating partnerships like with Cybin for phase 3 depression treatment. An addition, it made moves to acquire Solventum’s purification and filtration business, portraying a strong financial capability and a favourable position amongst billionaire Quants’ stock picks. Still,
TMO is facing challenges of tariff hits and research funding cuts which led to a reduction in their 2025 profit forecast. Regardless, TMO has been strengthening its long-term advantage and it is expected to see robust 2025 profit due to improved demand for its tools and services.
Laudable recent advances include the launch of more sustainable large-capacity and superspeed centrifuges with next-generation natural refrigerant cooling system.
Thermo Fisher Scientific TMO News Analytics from Thu, 07 Nov 2024 08:00:00 GMT to Fri, 06 Jun 2025 17:59:57 GMT -
Rating 3
- Innovation 5
- Information 6
- Rumor -2
